New treatments for PsA meet targeted therapy goals.
作者信息
Mease Philip J
机构信息
Swedish Medical Center and Providence St. Joseph Health, Seattle, WA, USA.
University of Washington School of Medicine, Seattle, WA, USA.
出版信息
Nat Rev Rheumatol. 2021 Feb;17(2):77-78. doi: 10.1038/s41584-020-00561-3.
PMID:33328615
Abstract
摘要
相似文献
1
New treatments for PsA meet targeted therapy goals.银屑病关节炎的新疗法达到了靶向治疗目标。
Nat Rev Rheumatol. 2021 Feb;17(2):77-78. doi: 10.1038/s41584-020-00561-3.
2
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.司库奇尤单抗，一种白细胞介素-17A特异性单克隆抗体，用于治疗初治的活动性银屑病关节炎患者：III期试验SPIRIT-P1的24周随机、双盲、安慰剂对照及活性（阿达木单抗）对照阶段的结果
Ann Rheum Dis. 2017 Jan;76(1):79-87. doi: 10.1136/annrheumdis-2016-209709. Epub 2016 Aug 23.
3
Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.特稿：2018 年美国风湿病学会/国家银屑病基金会银屑病关节炎治疗指南。
Arthritis Rheumatol. 2019 Jan;71(1):5-32. doi: 10.1002/art.40726. Epub 2018 Nov 30.
4
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).依奇珠单抗治疗活动性银屑病关节炎患者的疗效和安全性：一项 III 期研究（SPIRIT-P1）的 52 周结果。
J Rheumatol. 2018 Mar;45(3):367-377. doi: 10.3899/jrheum.170429. Epub 2017 Dec 15.
5
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.司库奇尤单抗治疗活动性银屑病关节炎（EXCEED）：一项双盲、平行组、随机、主动对照、3b 期临床试验。
Lancet. 2020 May 9;395(10235):1496-1505. doi: 10.1016/S0140-6736(20)30564-X.
6
Is there a need for new agents with novel mechanisms of action in psoriatic arthritis?银屑病关节炎中是否需要具有新型作用机制的新型药物？
Ann Rheum Dis. 2014 Jun;73(6):951-3. doi: 10.1136/annrheumdis-2013-204934.
7
Subacute thyroiditis in a patient with psoriatic arthritis switched from secukinumab to adalimumab: a case report and literature review.接受司库奇尤单抗治疗的银屑病关节炎患者转换用阿达木单抗后发生亚急性甲状腺炎：病例报告及文献复习。
Mod Rheumatol Case Rep. 2021 Jan;5(1):36-39. doi: 10.1080/24725625.2020.1741116. Epub 2020 Jul 31.
8
New biological treatments for psoriatic arthritis.银屑病关节炎的新型生物治疗方法。
Isr Med Assoc J. 2014 Oct;16(10):643-5.
9
Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals.治疗银屑病关节炎时起效时间：荟萃分析和生成置信区间的新方法。
Rheumatol Int. 2019 Apr;39(4):605-618. doi: 10.1007/s00296-019-04244-5. Epub 2019 Jan 25.
10
Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology.意大利风湿病学会2017年更新：生物制剂及其他新型药物用于治疗银屑病关节炎的推荐意见
Clin Exp Rheumatol. 2017 Nov-Dec;35(6):991-1010. Epub 2017 Nov 28.
Zotero 插件